证券代码：002840 证券简称：华统股份 公告编号：2025-059 浙江华统肉制品股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 以上议案具体内容详见同日公司在《证券时报》、 《证券日报》、 《中国证券报》 及巨潮资讯网（www.cninfo.com.cn）披露的《关于调整募集资金投资项目拟投入 募集资金金额的公告》。 的议案》 经审核，监事会认为：公司本次使用部分募集资金向子公司提供借款以实施 募投项目履行了必要的审议程序，符合相关法律法规、规范性文件及公司内部制 度的要求，不影响募投项目的正常实施，不存在变相改变募集资金用途和损害股 东利益的情况。因此，公司监事会同意公司本次使用部分募集资金向子公司提供 借款以实施募投项目事项。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 浙江华统肉制品股份有限公司（以下简称"公司"）第五届监事会第十六次 会议于 2025 年 5 月 13 日以电子邮件、电话通讯等形式发出通知，并于 2025 年 名，实际到会监事 3 名，其中卢冲冲先生采用通讯方式表决。会议由监事会主席 ...

Core Viewpoint - The company, Shenzhen Qingyi Optoelectronics Co., Ltd., is utilizing raised funds to increase capital and provide loans to its wholly-owned subsidiary to implement fundraising investment projects, which aligns with its strategic planning and long-term interests [1][6]. Summary of Fundraising Situation - The company issued 48 million A-shares at a price of RMB 25.00 per share, raising a total of RMB 120,000.00 million, with a net amount of RMB 118,700.94 million after deducting issuance costs of RMB 1,299.06 million [1][2]. - The funds are managed in a dedicated account, adhering to regulatory requirements and agreements with the sponsor and the bank [1]. Summary of Investment Projects - The total amount raised will be used entirely for investment projects, with adjustments made to the proposed investment amounts based on actual project needs [2]. - The total investment for the high-precision mask production base construction project is RMB 140,465.97 million, with the adjusted amount for fundraising investment projects being RMB 118,700.94 million [2]. Summary of Capital Increase and Loan to Subsidiary - The company plans to increase capital in its subsidiary, Foshan Qingyi, by RMB 40,000 million, raising its registered capital from RMB 20,000 million to RMB 60,000 million [3][4]. - The funding source for this capital increase has been adjusted from self-owned funds to raised funds, with the loan duration until the completion of the investment project [4]. Basic Information of the Subsidiary - Foshan Qingyi was established on September 4, 2023, with a registered capital of RMB 20,000 million and is wholly owned by Shenzhen Qingyi Optoelectronics [4]. - The subsidiary's total assets are RMB 39,221.35 million, with net assets of RMB 19,531.37 million, and it reported a net loss of RMB 466.59 million [4]. Purpose and Impact of the Capital Increase and Loan - The use of raised funds for capital increase and loans is essential for the implementation of the investment project, enhancing the subsidiary's competitiveness and aligning with the company's long-term strategy [5][6]. Fundraising Management Post-Increase - The capital increase and loan will be deposited in a special account for raised funds, with strict adherence to regulatory agreements for effective management [5]. Approval Process - The board of directors and the supervisory board approved the use of raised funds for the capital increase and loan, which falls within the board's approval authority [5]. Supervisory Board Opinion - The supervisory board supports the use of raised funds for the capital increase and loan, viewing it as beneficial for the project's development and the company's long-term needs [5][6]. Sponsor's Verification Opinion - The sponsor confirms that the use of raised funds complies with relevant regulations and does not alter the intended use of funds or harm shareholder interests [6].

Group 1 - The core viewpoint of the report is to summarize the sponsorship activities and compliance of Huatai United Securities in relation to the initial public offering (IPO) of Jiahe Meikang (Beijing) Technology Co., Ltd. on the Sci-Tech Innovation Board [1][3][10] - The issuer, Jiahe Meikang, has a registered capital of 137,585,598 yuan and was listed on December 14, 2021, with the stock code 688246.SH [1][3] - The total net proceeds from the IPO amounted to 1,240,457,179.15 yuan, which were allocated to various projects including electronic medical record development and operational funds [4][10] Group 2 - During the continuous supervision period, the sponsor conducted semi-annual inspections of the use and storage of raised funds, ensuring compliance with regulations [3][4] - The sponsor issued a total of 18 verification opinions regarding the issuer's use of raised funds and did not issue any dissenting opinions [4][10] - The issuer's shareholders, specifically the Xianning Kaixuan Opportunity Growth Fund, failed to timely fulfill commitments related to share reduction, leading to regulatory actions [5][7] Group 3 - The issuer discovered accounting errors in the financial statements for 2022 and 2023, which were corrected through retrospective adjustments approved by the board [10][11] - The sponsor confirmed that the issuer complied with relevant regulations in the use of raised funds and maintained proper disclosure practices [10][12] - As of December 31, 2024, the raised funds had not been fully utilized, and the sponsor will continue to oversee the usage until completion [12]

Group 1 - Daqian Energy's stock closed at 21.11 yuan, with a decline of 5.12%, resulting in a total market capitalization of 45.285 billion yuan [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 22, 2021, with an initial public offering (IPO) of 300 million shares at a price of 21.49 yuan per share [1] - The total funds raised from the IPO amounted to 644.7 million yuan, with a net amount of 606.719 million yuan, exceeding the original plan by 106.719 million yuan [1] Group 2 - In 2022, Daqian Energy issued A-shares to specific investors, raising a total of approximately 10.999 billion yuan at a price of 51.79 yuan per share [2] - The net amount raised from this issuance, after deducting issuance costs, was approximately 10.937 billion yuan, which was fully utilized by the end of 2022 [2] - The stock price is currently below the issuance price [2] Group 3 - Daqian Energy's total fundraising from both IPO and subsequent issuance amounts to 17.447 billion yuan [3] - For the year 2023, the company reported a revenue of approximately 741.052 million yuan, a year-on-year decline of 54.62%, and a net profit attributable to shareholders of -271.813 million yuan [3] - In the first quarter of 2025, the company reported a revenue of approximately 90.725 million yuan, a year-on-year decline of 69.57%, with a net profit of -55.802 million yuan [3]

中原证券股份有限公司 关于无锡智能自控工程股份有限公司 2023 年度以简易程序 向特定对象发行股票持续督导之保荐总结报告书 中原证券股份有限公司（以下简称"中原证券"或"保荐机构"）作为无锡 智能自控工程股份有限公司（以下简称"智能自控"、"发行人"或"公司"） 券发行上市保荐业务管理办法》《深圳证券交易所股票上市规则》《深圳证券交 易所上市公司自律监管指引第 13 号——保荐业务》等有关规定，对智能自控的 持续督导时间为该公司发行股票上市当年剩余时间及其后 1 个完整的会计年度， 智能自控股票于 2023 年 9 月 11 日起在深圳证券交易所上市，其持续督导期为 限已满，中原证券根据相关法律法规，出具本保荐总结报告。 一、保荐机构及保荐代表人承诺 遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法律责任。 证监会"）对保荐总结报告书相关事项进行的任何质询和调查。 管理办法》的有关规定采取的监管措施。 二、保荐机构基本情况 | 情况 | 内容 | | | | --- | --- | --- | --- | | 保荐机构名称 | 中原证券股份有限公司 | | | | 注册地址 | 10 郑州市郑东新 ...

Core Viewpoint - The report provides an overview of the fundraising activities and the utilization of the raised funds by Beijing Sanfu Outdoor Products Co., Ltd, confirming that the funds have been used in accordance with regulatory guidelines and for the intended projects [1][2]. Fundraising Situation - The company raised a total of RMB 193.18 million through a non-public offering of 12,218,843 shares at RMB 15.81 per share, with net proceeds amounting to RMB 185.99 million after deducting issuance costs of RMB 7.19 million [2][5]. - The funds were deposited into a dedicated account on September 27, 2021, and verified by RSM China [1][2]. Fund Management - The company established a fundraising management system to ensure the proper use of funds, adhering to principles of regulation, safety, efficiency, and transparency [2]. - A tripartite supervision agreement was signed with Beijing Bank and Xinda Securities to manage the funds [2]. Fund Utilization - As of December 31, 2024, the total amount of funds utilized was RMB 185.99 million, with RMB 146.70 million allocated to the committed investment project and RMB 39.30 million used to supplement working capital [2][3]. - The company generated interest income of RMB 2.27 million and investment income of RMB 2.31 million from the funds [3][5]. Project Adjustments - The company adjusted the internal structure of the investment project, reallocating funds from facility and equipment purchases to store upgrades and marketing for the X-BIONIC brand [3][4]. - The adjustments were made to enhance operational efficiency and focus on brand promotion amidst industry challenges [4]. Remaining Funds - As of December 31, 2024, there were no remaining funds from the previous fundraising activities, as all funds were utilized or reallocated [4][5]. - The company permanently supplemented working capital with the remaining funds, totaling RMB 39.30 million, after the closure of the fundraising account [5]. Project Performance - The X-BIONIC project has shown stable revenue growth, with the company focusing on expanding sales channels and enhancing marketing efforts [4][5]. - The project has met its expected performance metrics, with a cumulative production utilization rate indicating successful implementation [5].

南京泉峰汽车精密技术股份有限公司 截至 2024 年 12 月 31 日止 前次募集资金使用情况报告的鉴证报告 KPMG Huazhen LLP 毕马威华振会计师事务所 Oriental Plaza 中国北京 Beijing 100738 东方广场毕马威大楼 8 层 China 邮政编码:100738 Telephone +86 (10) 8508 5000 电话 +86 (10) 8508 5000 Fax +86 (10) 8518 5111 传真 +86 (10) 8518 5111 Internet kpmg.com/cn 网址 kpmg.com/cn 关于南京泉峰汽车精密技术股份有限公司 前次募集资金使用情况报告的鉴证报告 毕马威华振专字第 2503408 号 南京泉峰汽车精密技术股份有限公司董事会： 我们接受委托，对后附的南京泉峰汽车精密技术股份有限公司（以下简称"泉峰汽车公 司"）于 2019 年 5 月通过首次公开发行股票、2021 年 9 月通过公开发行可转换公司债券、 证业务，就前次募集资金使用情况报告是否在所有重大方面按照中国证券监督管理委员会颁 布的《监管规则适用指引——发行类第 7 ...

国泰海通证券股份有限公司关于杭州爱科科技股份有限公司2024年度持续督导跟踪报告显示，2024年， 爱科科技营业收入同比增长17.58%，主要受益于境内外下游行业需求稳定增长及公司市场开拓。归属 于上市公司股东的净利润同比下降11.00%，主要因加大研发投入、并购费用及人力成本上升。公司持 续强化核心技术优势，截至2024年末，已获授权发明专利72项、实用新型专利89项及软件著作权147 项。2024年研发投入同比增长28.48%，累计申请境内外专利265项。募集资金使用合规，累计已使用 223,381,158.67元，剩余17,529,159.12元。控股股东、实际控制人等持有的公司股份不存在质押、冻结及 减持情形。公司不存在重大违规事项。 截至2025年5月9日收盘，爱科科技（688092）报收于21.17元，较上周的20.65元上涨2.52%。本周，爱 科科技5月8日盘中最高价报21.66元。5月6日盘中最低价报20.65元。爱科科技当前最新总市值17.51亿 元，在专用设备板块市值排名170/177，在两市A股市值排名4978/5145。 国泰海通证券股份有限公司关于杭州爱科科技股份有限公司首次公开发 ...

东亚药业发行费用合计1.02亿元，其中，保荐机构东兴证券股份有限公司获得保荐及承销费用6143.87万 元。 据公司4月30日披露的《东兴证券股份有限公司关于浙江东亚药业股份有限公司2024年度募集资金存放 与使用情况专项核查报告》，根据中国证监会批复(证监许可〔2023〕1165号)，公司获准向不特定对象 | 项目 | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减变动幅度(%) | | 营业收入 | 190, 921, 213. 83 | 352. 582. 674. 10 | -45. 85 | | 归属于上市公司股东的净 | -6, 919, 576. 54 | 24, 039, 198. 04 | -128.78 | | 利润 | | | | | 归属于上市公司股东的扣 | -10, 505, 893. 27 | 20, 376, 579. 89 | -151. 56 | | 除非经常性损益的净利润 | | | | | 经营活动产生的现金流量 | -134, 527, 926. 86 | -97, 089, 771. 88 ...

Group 1 - The company announced a change in accounting policies based on new regulations issued by the Ministry of Finance, which will take effect on January 1, 2024, and December 31, 2024, respectively [2][3][4] - The change in accounting policies is deemed reasonable and will not have a significant impact on the company's financial status, operating results, or cash flow [5][6] Group 2 - The company appointed Zhongqin Wanxin Certified Public Accountants as the financial and internal control audit institution for the year 2025, with an audit fee of 2.9 million yuan [6][13] - Zhongqin Wanxin has been providing audit services to the company for 22 consecutive years and possesses the necessary qualifications for auditing listed companies [8][9] Group 3 - The company expects a total of 69.62 million yuan in daily related transactions for the year 2025 with its affiliated companies [21] - The related transactions are considered routine and do not pose significant risks to the company's operations or financial health [28][35] Group 4 - The company plans to conclude the "Lianhua Qingwen series product capacity enhancement project" and terminate the "Lianhua Qingwen capsule international registration project," reallocating the surplus funds to supplement working capital permanently [41][42] - The total surplus funds from these projects amount to 21.46 million yuan, which will be used to support the company's daily operations [52][53] Group 5 - The company will hold its 2024 annual general meeting on May 26, 2025, allowing shareholders to participate both in person and via online voting [56][58] - The meeting will address various resolutions that have been approved by the board and supervisory committee [65][66]